Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2005-2009

  Naderer, Odin J ^a   Dumont, Etienne ^a   Zhu, John ^a   Kurtinecz, Milena ^a   Jones, Lori S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; GSK 1322322; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LIPID DIET; MALE; MUSCULOSKELETAL PAIN; OROPHARYNX PAIN; PH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; DIETARY FATS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FASTING; HEADACHE; HUMANS; HYDROXAMIC ACIDS; MIDDLE AGED;

EID: 84876223355     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01779-12     Document Type: Article

References (15)

1. Schmieder R, Edwards R. 2012. Insights into antibiotic resistance through metagenomic approaches. Future Microbiol. 7:73-89.
2. Rehm SJ, Tice A. 2010. Staphylococcus aureus: methicillin-susceptible S. aureus to methicillin-resistant S. aureus and vancomycin-resistant S. aureus. Clin. Infect. Dis. 51(Suppl 2):S176-S182. doi:10.1086/653518.
3. Song JH, Chung DR. 2010. Respiratory infections due to drug-resistant bacteria. Infect. Dis. Clin. North Am. 24:639-653.
4. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. 2010. Sources of novel antibiotics - aside the common roads. Appl. Microbiol. Biotechnol. 88:1261-1267.
5. Lewandowski T, Peters T, Simon N, Kulkarni S. 2010. Potent activity of GSK1322322 a novel peptide deformylase inhibitor in a Haemophilus influenzae and Streptococcus pneumoniae respiratory tract infection model. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http://www.icaac.org/.
6. Apfel CM, Locher H, Evers S, Takács B, Hubschwerlen C, Pirson W, Page MGP, Keck W. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45:1058-1064.
7. Jain R, Chen D, White RJ, Patel DV, Yuan Z. 2005. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 12:1607-1621.
8. Aubart K, Benowitz A, Campobasso N, Dreabit J, Fang Y, Karpinski J, Kelly S, Liao X, Lee J, Mercer D, Lewandowski T, VanAller G, Zonis R, Christensen S, Zalacain M. 2010. Hydrazinopyrimidines as a new class of peptide deformylase inhibitors. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http://www .icaac.org/.
9. Lewandowski T, Demarsh P, Peters T, Kulkarni S. 2010. Potent activity of GSK1322322 a novel peptide deformylase inhibitor after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http://www.icaac.org/.
10. Naderer OJ, Jones LS, Zhu J, Kurtinecz M, Dumont E. 2010. A novel antibacterial peptide deformylase inhibitor (GSK1322322): first time in human safety and pharmacokinetics. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http: //www.icaac.org/.
11. Butler D, Chen D, O'Dwyer K, Zalacain M. 2010. Two methodologies confirm the unique potent sub-MIC effect of peptide deformylase inhibitors on the growth of Staphylococcus aureus. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http://www.icaac.org/.
12. Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN. 2011. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J. Clin. Microbiol. 49:3928-3930.
13. Sanofi-Aventis US, LLC. 2010. Rifater package insert. Sanofi-Aventis US, LLC, Bridgewater, NJ.
14. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L, Desmeules J, Hochstrasser D. 2006. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 62:423-429.
15. Singley C, Hoover J, DeMarsh P, Elefante P, Zalacain M. 2010. Efficacy of PDF inhibitor GSK1322322 against abscess infections caused by MRSA using a computer-controlled infusion system to recreate human PK profiles in rats. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010. http://www.icaac.org/.